

Krishnansu S Tewari

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6423505/publications.pdf>

Version: 2024-02-01

128
papers

7,593
citations

87888

38
h-index

58581

82
g-index

135
all docs

135
docs citations

135
times ranked

7462
citing authors

#	ARTICLE	IF	CITATIONS
1	Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 968-977.	1.6	38
2	Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer – an ancillary data analysis of the VELIA trial. <i>Gynecologic Oncology</i> , 2022, 164, 278-287.	1.4	6
3	Patient reported outcomes for cisplatin and radiation followed by carboplatin/paclitaxel versus carboplatin/paclitaxel for locally advanced endometrial carcinoma: An NRG oncology study. <i>Gynecologic Oncology</i> , 2022, 164, 428-436.	1.4	5
4	Survival with Cemiplimab in Recurrent Cervical Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 544-555.	27.0	182
5	TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 3289-3300.	1.6	19
6	The current landscape of molecular profiling in the treatment of epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 160, 333-345.	1.4	40
7	Should adjuvant chemotherapy be formally studied among patients found to have pelvic lymph node metastases following radical hysterectomy with lymphadenectomy for early-stage cervical cancer?. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e62.	2.2	3
8	Niraparib in the maintenance treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: safety and efficacy. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 475-480.	2.4	3
9	Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study. <i>Gynecologic Oncology</i> , 2021, 161, 113-121.	1.4	42
10	Utilizing an interim fertility analysis of the OVAL study (VB-111-701/GOG 3018) for potential reduction of risk: A phase III, double blind, randomized controlled trial of ofranergene obadenovec (VB-111) and weekly paclitaxel in patients with platinum resistant ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 161, 496-501.	1.4	7
11	Lung cancer diagnosed on pap smear: A case report and review of the literature. <i>Gynecologic Oncology Reports</i> , 2021, 36, 100776.	0.6	0
12	Correlation of imaging and plasma based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC). <i>Gynecologic Oncology</i> , 2021, 161, 382-388.	1.4	7
13	Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node: Results of GROINSS-V II. <i>Journal of Clinical Oncology</i> , 2021, 39, 3623-3632.	1.6	69
14	Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer. <i>New England Journal of Medicine</i> , 2021, 385, 1856-1867.	27.0	440
15	Beyond Sedlis – A novel histology-specific nomogram for predicting cervical cancer recurrence risk: An NRG/GOG ancillary analysis. <i>Gynecologic Oncology</i> , 2021, 162, 532-538.	1.4	22
16	De-implementation and substitution of clinical care processes: stakeholder perspectives on the transition to primary human papillomavirus (HPV) testing for cervical cancer screening. <i>Implementation Science Communications</i> , 2021, 2, 108.	2.2	5
17	RaPiDS (GOG-3028): randomized Phase II study of balstilimab alone or in combination with zalifrelimab in cervical cancer. <i>Future Oncology</i> , 2021, 17, 3433-3443.	2.4	21
18	Visual inspection with acetic acid screening for cervical cancer among women receiving antiretroviral therapy for human immunodeficiency virus infection in northern Tanzania. <i>Journal of Obstetrics and Gynaecology Research</i> , 2021, 47, 4365-4370.	1.3	1

#	ARTICLE	IF	CITATIONS
19	Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study. <i>Gynecologic Oncology</i> , 2021, , .	1.4	1
20	Reply to Farolfi et al and Haines et al. <i>Journal of Clinical Oncology</i> , 2020, 38, 173-174.	1.6	0
21	Multimodality screening and prevention of cervical cancer in sub-Saharan Africa: a collaborative model. <i>Current Opinion in Obstetrics and Gynecology</i> , 2020, 32, 28-35.	2.0	11
22	Fertility preserving treatment for gynecologic malignancies: a review of recent literature. <i>Current Opinion in Obstetrics and Gynecology</i> , 2020, 32, 51-56.	2.0	5
23	Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209). <i>Journal of Clinical Oncology</i> , 2020, 38, 3841-3850.	1.6	155
24	Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study. <i>Gynecologic Oncology</i> , 2020, 159, 79-87.	1.4	6
25	Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncologyâ€™Gynecologic Oncology Group Study 240 (NCT 00803062). <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2363-2370.	4.1	15
26	Philip John DiSaia, MD: Available Light & The Origin of Storms. <i>Journal of Obstetrics and Gynaecology Research</i> , 2020, 46, 959-988.	1.3	0
27	Robotic surgery for gynecologic cancers: indications, techniques and controversies. <i>Journal of Obstetrics and Gynaecology Research</i> , 2020, 46, 828-843.	1.3	11
28	Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer. <i>Future Oncology</i> , 2020, 16, 225-246.	2.4	63
29	Cost-effectiveness of niraparib, rucaparib, and olaparib for treatment of platinum-resistant, recurrent ovarian carcinoma. <i>Gynecologic Oncology</i> , 2020, 157, 500-507.	1.4	23
30	Gynecologic cancer in pregnancy. <i>Gynecologic Oncology</i> , 2020, 157, 799-809.	1.4	51
31	Measurements of adiposity as prognostic biomarkers for survival with anti-angiogenic treatment in epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group ancillary data analysis of GOG 218. <i>Gynecologic Oncology</i> , 2019, 155, 69-74.	1.4	10
32	Evidence-Based Treatment Paradigms for Management of Invasive Cervical Carcinoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 2472-2489.	1.6	32
33	Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 1929-1939.	27.0	217
34	Cervical cancer in Tanzania: A systematic review of current challenges in six domains. <i>Gynecologic Oncology Reports</i> , 2019, 29, 40-47.	0.6	37
35	Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 2317-2328.	1.6	289
36	Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 2317-2326.	27.0	326

#	ARTICLE	IF	CITATIONS
37	Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 1380-1390.	1.6	178
38	Immune Checkpoint Blockade in PD-L1-Positive Platinum-Refractory Cervical Carcinoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 1449-1454.	1.6	8
39	A phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND#) Tj ETQq1 1 0.784314 rgBT /Overl who are in second or third complete remission: An NRG Oncology/GOG study. <i>Gynecologic Oncology</i> , 2019, 155, 393-399.	1.4	20
40	Therapeutic vaccination using HPV 16 E7 to eradicate CIN3. <i>Journal of Gynecologic Oncology</i> , 2019, 30, e119.	2.2	2
41	Rational design for cervical cancer therapeutics: cellular and non-cellular based strategies on the horizon for recurrent, metastatic or refractory cervical cancer. <i>Expert Opinion on Drug Discovery</i> , 2018, 13, 445-457.	5.0	19
42	Pharmacokinetic drug evaluation of niraparib for the treatment of ovarian cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 543-550.	3.3	10
43	Cervical cancer - State of the science: From angiogenesis blockade to checkpoint inhibition. <i>Gynecologic Oncology</i> , 2018, 148, 609-621.	1.4	96
44	Clinical trial experience with CA4P anticancer therapy: focus on efficacy, cardiovascular adverse events, and hypertension management. <i>Gynecologic Oncology Research and Practice</i> , 2018, 5, 1.	3.6	62
45	Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2018, 149, 525-530.	1.4	24
46	Oncofertility in the setting of advanced cervical cancer - A case report. <i>Gynecologic Oncology Reports</i> , 2018, 24, 27-29.	0.6	3
47	Invasive Cervical Cancer. , 2018, , 38-104.e15.		2
48	Cancer in Pregnancy. , 2018, , 353-418.e11.		0
49	Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 Study. <i>Gynecologic Oncology</i> , 2018, 148, 49-55.	1.4	14
50	Impact of tumour histology on survival in advanced cervical carcinoma: an NRG Oncology/Gynaecologic Oncology Group Study. <i>British Journal of Cancer</i> , 2018, 118, 162-170.	6.4	20
51	Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study. <i>Clinical Cancer Research</i> , 2018, 24, 777-783.	7.0	171
52	Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma: A Phase III NRG Oncology/Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 3324-3330.	1.6	61
53	Targeted treatment of advanced ovarian cancer: spotlight on rucaparib. <i>Therapeutics and Clinical Risk Management</i> , 2018, Volume 14, 2189-2201.	2.0	8
54	Bevacizumab in Cervical Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2018, 24, 187-192.	2.0	19

#	ARTICLE	IF	CITATIONS
55	The Ecstasy of Gold: Patent Expirations for Trastuzumab, Bevacizumab, Rituximab, and Cetuximab. Recent Patents on Biotechnology, 2018, 12, 101-112.	0.8	12
56	Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study. Gynecologic Oncology, 2018, 151, 257-263.	1.4	20
57	A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer. Gynecologic Oncology, 2018, 150, 274-281.	1.4	105
58	Bevacizumab and paclitaxel+carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, The, 2017, 18, 779-791.	10.7	460
59	High stathmin expression is a marker for poor clinical outcome in endometrial cancer: An NRG oncology group/gynecologic oncology group study. Gynecologic Oncology, 2017, 146, 247-253.	1.4	23
60	Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology, 2017, 147, 396-401.	1.4	6
61	A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology, 2017, 146, 554-559.	1.4	15
62	Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet, The, 2017, 390, 1654-1663.	13.7	424
63	An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience. Gynecologic Oncology, 2017, 147, 243-249.	1.4	61
64	The safety and efficacy of bevacizumab in the treatment of patients with recurrent or metastatic cervical cancer. Expert Review of Anticancer Therapy, 2017, 17, 191-198.	2.4	18
65	Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. Journal of Clinical Oncology, 2016, 34, 2279-2286.	1.6	63
66	Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group ancillary data analysis. Gynecologic Oncology, 2016, 143, 294-301.	1.4	31
67	Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 1247-1253.	3.3	50
68	Clinical Trials of Antiangiogenesis Therapy in Recurrent/Persistent and Metastatic Cervical Cancer. Oncologist, 2016, 21, 576-585.	3.7	31
69	Impact of histology and surgical approach on survival among women with early-stage, high-grade uterine cancer: An NRG Oncology/Gynecologic Oncology Group ancillary analysis. Gynecologic Oncology, 2016, 143, 460-465.	1.4	79
70	Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study. Gynecologic Oncology, 2016, 143, 484-489.	1.4	6
71	Fifth annual workshop of cytoreductive surgery for advanced ovarian cancer and peritoneal surface malignancies. Gynecologic Oncology Research and Practice, 2016, 3, 10.	3.6	1
72	New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors. Current Treatment Options in Oncology, 2016, 17, 12.	3.0	28

#	ARTICLE	IF	CITATIONS
73	Changing paradigms in the systemic treatment of advanced cervical cancer. American Journal of Obstetrics and Gynecology, 2016, 214, 22-30.	1.3	162
74	Recent Patents for Homologous Recombination Deficiency Assays Among Women with Ovarian Cancer. Recent Patents on Biotechnology, 2016, 9, 86-101.	0.8	1
75	A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation â€” An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology, 2015, 137, 386-391.	1.4	224
76	US FDA oncology drug approvals in 2014. Future Oncology, 2015, 11, 1931-1945.	2.4	5
77	Reply to W.A.A. Tjalma and J.S. Grossman. Journal of Clinical Oncology, 2015, 33, 966-966.	1.6	3
78	Prospective Validation of Pooled Prognostic Factors in Women with Advanced Cervical Cancer Treated with Chemotherapy with/without Bevacizumab: NRG Oncology/GOG Study. Clinical Cancer Research, 2015, 21, 5480-5487.	7.0	59
79	The 21st Century Handbook of Clinical Ovarian Cancer. , 2015, , .		6
80	Exploring the Therapeutic Rationale for Angiogenesis Blockade in Cervical Cancer. Clinical Therapeutics, 2015, 37, 9-19.	2.5	18
81	Immunotherapy: An Evolving Paradigm in the Treatment of Advanced Cervical Cancer. Clinical Therapeutics, 2015, 37, 20-38.	2.5	46
82	Integration of bevacizumab with chemotherapy doublets for advanced cervical cancer. Expert Opinion on Pharmacotherapy, 2015, 16, 675-683.	1.8	11
83	Development of Olaparib for BRCA-Deficient Recurrent Epithelial Ovarian Cancer. Clinical Cancer Research, 2015, 21, 3829-3835.	7.0	40
84	Full-Thickness Skin Grafts for Neovaginal Construction in Mayerâ€™sâ€”Rokitanskyâ€”KÅ½sterâ€”Hauser Syndrome. Journal of Gynecologic Surgery, 2015, 31, 52-57.	0.1	2
85	Impact of race, socioeconomic status, and the health care system on the treatment of advanced-stage ovarian cancer in California. American Journal of Obstetrics and Gynecology, 2015, 212, 468.e1-468.e9.	1.3	73
86	A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer. Gynecologic Oncology, 2015, 137, 490-496.	1.4	52
87	Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncologyâ€™s Gynecologic Oncology Group protocol 240). Lancet Oncology, The, 2015, 16, 301-311.	10.7	122
88	Development of bevacizumab in advanced cervical cancer: pharmacodynamic modeling, survival impact and toxicology. Future Oncology, 2015, 11, 909-922.	2.4	15
89	Clinical implications for cediranib in advanced cervical cancer. Lancet Oncology, The, 2015, 16, 1447-1448.	10.7	6
90	Pharmacologic Management of Advanced Cervical Cancer: Antiangiogenesis Therapy and Immunotherapeutic Considerations. Drugs, 2015, 75, 1853-1865.	10.9	11

#	ARTICLE	IF	CITATIONS
91	A review of HER2-targeted therapy in breast and ovarian cancer: lessons from antiquity â€” CLEOPATRA and PENELOPE. <i>Future Oncology</i> , 2015, 11, 3113-3131.	2.4	17
92	Sentinel lymph node mapping of a breast cancer of the vulva: Case report and literature review. <i>World Journal of Clinical Oncology</i> , 2015, 6, 16.	2.3	13
93	Translational science. , 2015, , 61-82.		0
94	Anti-angiogenesis therapy in gynecologic malignancies. <i>Oncology</i> , 2015, 29, 350-60.	0.5	16
95	Beyond angiogenesis blockade: targeted therapy for advanced cervical cancer. <i>Journal of Gynecologic Oncology</i> , 2014, 25, 249.	2.2	31
96	Exploiting the therapeutic potential of the PI3K-AKT-mTOR pathway in enriched populations of gynecologic malignancies. <i>Expert Review of Clinical Pharmacology</i> , 2014, 7, 847-858.	3.1	17
97	Chemotherapy in the treatment of metastatic, persistent, and recurrent cervical cancer. <i>Current Opinion in Obstetrics and Gynecology</i> , 2014, 26, 314-321.	2.0	45
98	PARP inhibition and synthetic lethality in ovarian cancer. <i>Expert Review of Clinical Pharmacology</i> , 2014, 7, 613-622.	3.1	25
99	Updates on drug discovery in ovarian cancer. <i>Gynecologic Oncology Research and Practice</i> , 2014, 1, 3.	3.6	3
100	New world order(s): Healthcare metrics, international borders, and gravitational waves. <i>Gynecologic Oncology</i> , 2014, 133, 139-141.	1.4	0
101	Chemotherapy-induced neutropenia as a biomarker of survival in advanced ovarian carcinoma: An exploratory study of the Gynecologic Oncology Group. <i>Gynecologic Oncology</i> , 2014, 133, 439-445.	1.4	35
102	Improved Survival with Bevacizumab in Advanced Cervical Cancer. <i>New England Journal of Medicine</i> , 2014, 370, 734-743.	27.0	1,140
103	Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinomaâ€”Mechanistics, review of phase III randomized clinical trials, and regulatory implications. <i>Gynecologic Oncology</i> , 2014, 132, 496-505.	1.4	98
104	Targeting angiogenesis in advanced cervical cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2014, 6, 280-292.	3.2	32
105	Evidence-Based Therapy for Recurrent Cervical Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 2687-2690.	1.6	38
106	New Strategies in Advanced Cervical Cancer: From Angiogenesis Blockade to Immunotherapy. <i>Clinical Cancer Research</i> , 2014, 20, 5349-5358.	7.0	69
107	Pathologic Findings at Risk-Reducing Salpingo-Oophorectomy: Primary Results From Gynecologic Oncology Group Trial GOG-0199. <i>Journal of Clinical Oncology</i> , 2014, 32, 3275-3283.	1.6	115
108	Pemetrexed and Cisplatin for the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix: A Limited Access Phase II Trial of the Gynecologic Oncology Group. <i>Journal of Clinical Oncology</i> , 2014, 32, 2744-2749.	1.6	16

#	ARTICLE	IF	CITATIONS
109	Assessment of palliative care training in gynecologic oncology: A gynecologic oncology fellow research network study. <i>Gynecologic Oncology</i> , 2014, 134, 379-384.	1.4	31
110	Use of stereotactic radiosurgery in the treatment of gynecologic malignancies: A review. <i>World Journal of Radiology</i> , 2014, 6, 366.	1.1	9
111	Development of a platform for systemic antiangiogenesis therapy for advanced cervical cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2014, 12, 737-48.	0.3	3
112	Invasive Cervical Cancer. , 2012, , 51-119.e13.		15
113	Association of number of positive nodes and cervical stroma invasion with outcome of advanced endometrial cancer treated with chemotherapy or whole abdominal irradiation: A Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2012, 125, 87-93.	1.4	23
114	PRO: Patients With Metastatic/Recurrent Cervical Cancer Should be Treated With Cisplatin Plus Paclitaxel. <i>Clinical Ovarian Cancer & Other Gynecologic Malignancies</i> , 2011, 4, 90-93.	0.2	6
115	Drug Discovery in Ovarian Cancer. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2010, 5, 251-260.	1.6	12
116	PRO: Patients With Metastatic/Recurrent Cervical Cancer Should Be Treated With Cisplatin Plus Paclitaxel. <i>Clinical Ovarian Cancer & Other Gynecologic Malignancies</i> , 2010, 3, 14-17.	0.2	2
117	Beyond Platinum for Metastatic and Recurrent Carcinoma of the Cervix. <i>Onkologie</i> , 2009, 32, 552-554.	0.8	11
118	Recent Achievements and Future Developments in Advanced and Recurrent Cervical Cancer: Trials of the Gynecologic Oncology Group. <i>Seminars in Oncology</i> , 2009, 36, 170-180.	2.2	47
119	Supportive care for women with gynecologic cancers. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 227-241.	2.4	23
120	Multimodality Therapy for Locally Advanced Cervical Carcinoma: State of the Art and Future Directions. <i>Journal of Clinical Oncology</i> , 2007, 25, 2952-2965.	1.6	223
121	Tumors of the Cervix. , 2006, , 501-520.		0
122	Conservation of in vitro drug resistance patterns in epithelial ovarian carcinoma. <i>Gynecologic Oncology</i> , 2005, 98, 360-368.	1.4	30
123	Gynecologic oncology group trials of chemotherapy for metastatic and recurrent cervical cancer. <i>Current Oncology Reports</i> , 2005, 7, 419-434.	4.0	69
124	Primary invasive carcinoma of the vagina. <i>Cancer</i> , 2001, 91, 758-770.	4.1	55
125	Recent Advancements in the Treatment of Epithelial Ovarian Cancer*. <i>Journal of Obstetrics and Gynaecology Research</i> , 2001, 27, 61-75.	1.3	9
126	Neoadjuvant chemotherapy in the treatment of locally advanced cervical carcinoma in pregnancy. , 1998, 82, 1529-1534.		110

#	ARTICLE	IF	CITATIONS
127	Should Critical Care Medicine be a Formal Part of the Undergraduate Curriculum?. Journal of Intensive Care Medicine, 1996, 11, 13-18.	2.8	5
128	Phase III Randomized Trial of Maintenance Taxanes Versus Surveillance in Women With Advanced Ovarian/Tubal/Peritoneal Cancer: A Gynecologic Oncology Group 0212:NRG Oncology Study. Journal of Clinical Oncology, 0, , .	1.6	4